Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $16.94, for a total transaction of $47,432.00. Following the completion of the sale, the chief executive officer now directly owns 731,859 shares of the company’s stock, valued at approximately $12,397,691.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of Atara Biotherapeutics, Inc. (NASDAQ ATRA) traded down 2.52% during trading on Wednesday, reaching $15.45. 205,081 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $14.33 and its 200-day moving average price is $15.91. Atara Biotherapeutics, Inc. has a 52-week low of $11.80 and a 52-week high of $25.73. The stock’s market cap is $449.73 million.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Atara Biotherapeutics during the first quarter worth $132,000. DekaBank Deutsche Girozentrale purchased a new position in Atara Biotherapeutics during the first quarter worth $185,000. American International Group Inc. raised its position in Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares during the last quarter. Old West Investment Management LLC purchased a new position in Atara Biotherapeutics during the first quarter worth $512,000. Finally, Parametric Portfolio Associates LLC raised its position in Atara Biotherapeutics by 62.6% in the first quarter. Parametric Portfolio Associates LLC now owns 25,389 shares of the biotechnology company’s stock worth $522,000 after buying an additional 9,774 shares during the last quarter. 81.61% of the stock is currently owned by institutional investors.
A number of analysts recently weighed in on ATRA shares. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. Canaccord Genuity reissued a “buy” rating and issued a $47.00 price target on shares of Atara Biotherapeutics in a report on Friday, April 21st. Jefferies Group LLC reissued a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a report on Thursday, June 22nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, June 26th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $25.75.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
